银诺医药-B核心产品纳入《国家医保药品目录》

Core Viewpoint - The company, Silver诺医药-B (02591), has successfully included its core product, Isuparaglutide α, in the latest version of China's National Medical Insurance Drug List (2025 edition) for the treatment of Type 2 Diabetes (T2D) [1] Group 1 - The inclusion of Isuparaglutide α in the National Medical Insurance Drug List is a significant milestone for the company [1] - The updated National Medical Insurance Drug List will officially take effect on January 1, 2026 [1]